{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:30:04Z","timestamp":1783686604669,"version":"3.55.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term extension (LTE) of SELECT-COMPARE, a randomised controlled phase 3 trial of patients with active rheumatoid arthritis and inadequate response to methotrexate (MTX).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients on stable background MTX were randomised 2:2:1 to upadacitinib 15\u2009mg, placebo or adalimumab 40\u2009mg. Patients with an insufficient response were switched by week 26 from placebo to upadacitinib, upadacitinib to adalimumab or adalimumab to upadacitinib. Patients who completed the 48-week double-blind period could enter an LTE for up to 10 years. Safety and efficacy results were analysed here through 3 years. Treatment-emergent adverse events (AEs) were summarised based on exposure to upadacitinib and adalimumab. Efficacy was analysed by original randomised groups (non-responder imputation), as well as separately by treatment sequence (as observed).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Rates of several AEs were generally comparable between upadacitinib and adalimumab, including AEs leading to discontinuation, serious infections and serious AEs, malignancies, major adverse cardiac events, venous thromboembolism and deaths. Consistent with earlier results, herpes zoster, lymphopaenia, hepatic disorder and CPK elevation were reported at higher rates with upadacitinib versus adalimumab. In terms of efficacy, upadacitinib continued to show numerically better clinical responses than adalimumab over 3 years across all endpoints, including low disease activity and remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The safety profile of UPA 15\u2009mg was consistent with previous study-specific and integrated safety reports. Higher levels of clinical response continued to be observed with upadacitinib versus adalimumab through 3 years of treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002012","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T10:55:32Z","timestamp":1643972132000},"page":"e002012","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":97,"title":["Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"first","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G","family":"Peterfy","sequence":"additional","affiliation":[{"name":"Spire Sciences Inc, Boca Raton, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2356","authenticated-orcid":false,"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[{"name":"P\u00f4le de Recherche en Rhumatologie, Institut de Recherche Exp\u00e9rimentale et Clinique, UCL Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Swierkot","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Bu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2025090313573277000_8.1.e002012.1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090313573277000_8.1.e002012.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090313573277000_8.1.e002012.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2025090313573277000_8.1.e002012.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.187"},{"key":"2025090313573277000_8.1.e002012.5","first-page":"84","article-title":"Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis","volume":"9","author":"Louder","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2025090313573277000_8.1.e002012.6","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2025090313573277000_8.1.e002012.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2025090313573277000_8.1.e002012.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090313573277000_8.1.e002012.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2025090313573277000_8.1.e002012.10","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase III clinical programme","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313573277000_8.1.e002012.11","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of Upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"2025090313573277000_8.1.e002012.12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of Upadacitinib monotherapy in Methotrexate-Naive patients with Moderately-to-Severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, Multi-Country, randomized, double-blind, active Comparator-Controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313573277000_8.1.e002012.13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313573277000_8.1.e002012.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1418"},{"key":"2025090313573277000_8.1.e002012.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313573277000_8.1.e002012.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2281"},{"key":"2025090313573277000_8.1.e002012.17","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313573277000_8.1.e002012.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090313573277000_8.1.e002012.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2025090313573277000_8.1.e002012.20","first-page":"vi16","article-title":"The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission","volume":"51 Suppl 6","author":"Bykerk","year":"2012","journal-title":"Rheumatology"},{"key":"2025090313573277000_8.1.e002012.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80189-X"},{"key":"2025090313573277000_8.1.e002012.22","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2025090313573277000_8.1.e002012.23","first-page":"743","article-title":"How to read radiographs according to the Sharp\/van Der Heijde method","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"2025090313573277000_8.1.e002012.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350105"},{"key":"2025090313573277000_8.1.e002012.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2025090313573277000_8.1.e002012.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2025090313573277000_8.1.e002012.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090313573277000_8.1.e002012.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"2025090313573277000_8.1.e002012.29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1756-185X.13516","article-title":"Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data","volume":"22","author":"Lee","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025090313573277000_8.1.e002012.30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of Upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"2025090313573277000_8.1.e002012.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090313573277000_8.1.e002012.32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090313573277000_8.1.e002012.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208105"},{"key":"2025090313573277000_8.1.e002012.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"2025090313573277000_8.1.e002012.35","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11741"},{"key":"2025090313573277000_8.1.e002012.36","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0651-5"},{"key":"2025090313573277000_8.1.e002012.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"2025090313573277000_8.1.e002012.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2897"},{"key":"2025090313573277000_8.1.e002012.39","unstructured":"Ytterberg S , Bhatt D , Mikuls T . Safety and efficacy of tofacitinib vs tnf inhibitors in ra patients aged 50 years or older with one or more cardiovascular risks: results from a phase 3b\/4 randomized safety trial [abstract]. Arthritis Rheumatology 2021;73 https:\/\/acrabstracts.org\/abstract\/safety-and-efficacy-of-tofacitinib-vs-tnf-inhibitors-in-ra-patients-aged-50-years-or-older-with-one-or-more-cardiovascular-risks-results-from-a-phase-3b-4-randomized-safety-trial\/"},{"key":"2025090313573277000_8.1.e002012.40","article-title":"Benefit-Risk analysis of Upadacitinib compared with adalimumab in the treatment of patients with moderate-to-severe rheumatoid arthritis","author":"Conaghan","year":"2021","journal-title":"Rheumatol Ther"}],"updated-by":[{"DOI":"10.1136\/rmdopen-2021-002012corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:57:40Z","timestamp":1756933060000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,4]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/rmdopen-2021-002012"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002012","relation":{"correction":[{"id-type":"doi","id":"10.1136\/rmdopen-2021-002012corr1","asserted-by":"object"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}